Literature DB >> 3089944

Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion.

D M Ota, V B Grossie, J A Ajani, L C Stephens, K Nishioka.   

Abstract

The dose effects of continuous alpha-difluoromethylornithine (DFMO) infusion on red blood cell (RBC) polyamine levels, host toxicity and tumor growth were determined. Male rats with and without a transplantable methylcholanthrene-induced sarcoma received intravenously either 0.45% NaCl or DFMO at 500 mg, 1,000 mg, or 2,000 mg/kg body wt/day for 6 or 12 days. Dose-related inhibition of tumor growth was noted after the 12-day treatment. There were no changes in host carcass weight, food intake, plasma albumin, hematocrit or white blood cell counts. Platelet suppression was associated with the 1,000- and 2,000-mg doses with the 12-day treatment. Morphometry of the small intestine revealed mild but significant shortening of villi in the duodenum and jejunum at the 2,000-mg dose, but none of the animals developed diarrhea. The 500-mg DFMO dose reduced the rate of tumor growth without inducing platelet suppression or altering intestinal morphology. A decrease in RBC putrescine levels was noted at all doses. RBC spermidine levels increased with the 500-mg dose. RBC spermine levels were higher at all doses compared with controls. These results suggest that thrombocytopenia is the major dose-limiting side-effect of continuous DFMO infusion but does not occur at a dose of 500 mg/kg body wt/day.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3089944     DOI: 10.1002/ijc.2910380215

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

Review 1.  Mechanisms of cellular resistance to cisplatin.

Authors:  G A Hospers; N H Mulder; E G De Vries
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

2.  Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.

Authors:  V B Grossie; D M Ota; J A Ajani; K Nishioka
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.